ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag fda disease medicine pharma tuberculosis

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Take Two of These
Bob Grant | Jun 22, 2011 | 6 min read
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
Outwitting the Perfect Pathogen
Megan Scudellari | Jan 1, 2014 | 8 min read
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
Overcoming Resistance
The Scientist | Apr 1, 2014 | 10+ min read
In the face of bacterial threats that can evade modern medicines, researchers are trying every trick in the book to develop new, effective antibiotics.
Nice Shot
Megan Scudellari | Jan 1, 2010 | 10+ min read
By Megan Scudellari Nice Shot Why vaccines are pharma’s Next Big Thing. ILLUSTRATION BY Jason Raish Late at night, a feverish young girl shuffled into her father’s room complaining of a sore throat. Maurice Hilleman examined the swollen bumps on his daughter’s neck. It was 1963. She had the mumps, a common childhood disease at the time, caused by a virus that inflames the salivary glands. Most cases are mild, but severe inf
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th

Run a Search

ADVERTISEMENT